Buy Rating for Editas Medicine: Promising In Vivo CRISPR Platform and Strategic Growth Potential Amid Speculative Investment
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...
Promising Financial Position and Advancements Propel Editas Medicine to a ‘Buy’ Rating
JonesTrading analyst Soumit Roy has assigned their bullish stance on EDIT stock, giving a Buy rating today. Soumit Roy’s rating is based ...
GEN19h
“Give Cas a Chance”: Fyodor Urnov Says He Wants a CRISPR Revolution
An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.
ksby21h
Nobel Prize winner Dr. Jennifer Doudna making an appearance in Santa Barbara
Co-hosted by UC Santa Barbara Arts & Lectures and the Cancer Foundation of Santa Barbara, the talk will discuss CRISPR-Cas9 ...